Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Corvus Pharmaceuticals (CRVS) Shares Issued (2016 - 2026)

Corvus Pharmaceuticals' Shares Issued history spans 11 years, with the latest figure at $1.3 million for Q1 2026.

  • Quarterly Shares Issued rose 379.93% to $1.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$27.9 million through Mar 2026, down 256.77% year-over-year, with the annual reading at $684000.0 for FY2025, 96.32% down from the prior year.
  • Shares Issued came in at $1.3 million for Q1 2026, up from -$35.1 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $9.7 million in Q4 2024 to a low of -$35.1 million in Q4 2025.
  • The 4-year median for Shares Issued is $2.1 million (2025), against an average of -$1.0 million.
  • Year-over-year, Shares Issued plummeted 463.1% in 2025 and then skyrocketed 379.93% in 2026.
  • Corvus Pharmaceuticals' Shares Issued stood at $7.8 million in 2023, then increased by 23.3% to $9.7 million in 2024, then tumbled by 463.1% to -$35.1 million in 2025, then skyrocketed by 103.82% to $1.3 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Shares Issued are $1.3 million (Q1 2026), -$35.1 million (Q4 2025), and $2.9 million (Q3 2025).